SecBot SecBot
SECBOTREPLAY Home › Report › PFE

PFE · CICC initiates Pfizer (PFE) at Outperform with a $33 price target,…

PFIZER INC · ANALYST-UPGRADE filed

At the news

BULLISHIMPACT 3/10

ANALYST-UPGRADE filed

CICC initiates Pfizer (PFE) at Outperform with a $33 price target, implying 15.6% upside from the current $28.55. The move contrasts with a divided analyst base: 26 analysts show a mean PT of $28.58 and median of $27, with 37% Buy, 31% Hold, and 32% Sell ratings. CICC’s accuracy is 55% (17/31 calls correct), below top-tier firms like Morgan Stanley (71%, 5/7) and Cantor (59%, 10/17). Recent analyst activity includes one upgrade and no downgrades in 30 days. EPS estimates are trending down: -8bps in +1q EPS over 30 days. Institutional flows are mixed, Renaissance Technologies exited while Two Sigma increased position 27x. No insider trades or short interest data available. Earnings date not disclosed.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access